Cytarabine is a Intrathecal; Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Fresenius Kabi Usa, Llc. The primary component is Cytarabine.
| Product ID | 63323-120_6594799a-7b02-4847-aff7-1cb7842771bd |
| NDC | 63323-120 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Cytarabine |
| Generic Name | Cytarabine |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
| Marketing Start Date | 2004-11-29 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA076512 |
| Labeler Name | Fresenius Kabi USA, LLC |
| Substance Name | CYTARABINE |
| Active Ingredient Strength | 100 mg/mL |
| Pharm Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
| Marketing Start Date | 2004-11-29 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | ANDA |
| Application Number | ANDA076512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2004-11-29 |
| Ingredient | Strength |
|---|---|
| CYTARABINE | 100 mg/mL |
| SPL SET ID: | c4fdc56e-efd7-4825-a518-ef430b2b3df0 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 61703-303 | CYTARABINE | CYTARABINE |
| 61703-304 | Cytarabine | CYTARABINE |
| 61703-305 | Cytarabine | CYTARABINE |
| 61703-319 | Cytarabine | CYTARABINE |
| 63323-120 | Cytarabine | CYTARABINE |
| 67457-452 | Cytarabine | Cytarabine |
| 67457-454 | Cytarabine | Cytarabine |
| 67457-455 | cytarabine | cytarabine |
| 68083-337 | Cytarabine | Cytarabine |
| 68083-343 | Cytarabine | Cytarabine |
| 71288-108 | Cytarabine | Cytarabine |
| 71288-109 | Cytarabine | Cytarabine |
| 71288-168 | Cytarabine | Cytarabine |
| 71288-169 | Cytarabine | Cytarabine |